Expression and activity levels of matrix metalloproteinase-7 and in situ localization of caseinolytic activity in colorectal cancer

2014 ◽  
Vol 47 (13-14) ◽  
pp. 1265-1271 ◽  
Author(s):  
Didem Keles ◽  
Baha Arslan ◽  
Cem Terzi ◽  
Isil Tekmen ◽  
Ezgi Dursun ◽  
...  
2004 ◽  
Vol 59 (3) ◽  
pp. 385-392 ◽  
Author(s):  
Yuki Saitoh ◽  
Hideo Yanai ◽  
Shingo Higaki ◽  
Hiroaki Nohara ◽  
Tomoharu Yoshida ◽  
...  

2007 ◽  
Vol 121 (5) ◽  
pp. 1066-1071 ◽  
Author(s):  
Joan Maurel ◽  
Cristina Nadal ◽  
Xabier Garcia-Albeniz ◽  
Rosa Gallego ◽  
Enric Carcereny ◽  
...  

2018 ◽  
Vol 8 ◽  
Author(s):  
Mahmood Rasool ◽  
Arif Malik ◽  
Ahmad Ashar Ghuman ◽  
Muhammad Abdul Basit Ashraf ◽  
Mahwish Arooj ◽  
...  

2009 ◽  
Vol 16 (1) ◽  
pp. 311-317 ◽  
Author(s):  
Rosa Gallego ◽  
Jordi Codony-Servat ◽  
Xabier García-Albéniz ◽  
Enric Carcereny ◽  
Raquel Longarón ◽  
...  

Insulin-like growth factor-I (IGF-I) is thought to have antiapoptotic and mitogenic properties in colorectal cancer, whereas IGF-binding protein-3 (IGFBP-3) seems to exert a pro-apoptotic effect. Additionally, matrix metalloproteinase-7 (MMP-7), an enzyme with in vitro ability to degrade IGFBP-3, has been shown to be a prognostic factor in advanced colorectal cancer (ACRC). We studied whether chemotherapy treatment for ACRC modulates IGF-I, IGFBP-3, and MMP-7 serum levels. In 41 patients undergoing first-line therapy for ACRC, serum levels of IGF-I, IGFBP-3, and MMP-7 were measured with immunoassays at baseline and every 3 months until progressive disease, or a maximum of five determinations, during a chemotherapy regimen of either FOLFOX or FOLFIRI therapies. Associations were assessed for paired samples, using t-test or Wilcoxon ranks test depending on normality of the variable, verified with Shapiro-Wilk test. An average of four extractions (range 3–5) were done, for a total of 157 determinations. Mean pretreatment values of IGF-I, IGFBP-3, and MMP-7 were 83 (95% CI, 73–92) ng/ml, 2372 (95% CI, 2121–2623) ng/ml, and 10.6 (95% CI, 7.21–13.98) ng/ml respectively. No significant changes in IGF-I were found, but a significant increase in IGFBP-3 serum concentrations was observed during or after chemotherapy treatment without progressive disease, compared with basal levels (P<0.001). A significant decrease in IGFBP-3 to 1983 ng/ml (95% CI, 1675–2292) and a significant increase in MMP-7 levels to 14.6 (7.6–21.7) ng/ml were observed at progression of disease compared with baseline and treatment levels (P<0.001). This study shows that IGFBP-3 and MMP-7 serum levels change during chemotherapy treatment. The increased MMP-7 levels at disease progression support the hypothesis that this protease could play a role in acquired resistance by degrading IGFBP-3.


2004 ◽  
Vol 10 (24) ◽  
pp. 8243-8249 ◽  
Author(s):  
Koshi Mimori ◽  
Keishi Yamashita ◽  
Mitsuhiko Ohta ◽  
Keiji Yoshinaga ◽  
Kenji Ishikawa ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document